A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

NCT06025110 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class

Stopped The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.

Conditions

Interventions

Sponsor

ITB-Med LLC